Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080379 | 1.00 | ALDH1A1 (0.34) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2080381 | 1.00 | ALDH1A1 (0.34) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2078091 | 0.90 | USP2 (0.32) | ALDH1A1USP2ALOX15TDP1LMNA | |
| SCHEMBL2078658 | 0.85 | ATM (0.34) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2078653 | 0.85 | ATM (0.34) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2078656 | 0.85 | ATM (0.34) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2080986 | 0.83 | ALDH1A1 (0.38) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2080992 | 0.83 | ALDH1A1 (0.38) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2080989 | 0.83 | ALDH1A1 (0.38) | ALDH1A1USP2ALOX15TDP1HSD17B10 | |
| SCHEMBL2080553 | 0.79 | SMYD3 (0.43) | ALDH1A1USP2ALOX15TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906532-B2 | Antiserotonine agents; gastrointestinal disorders; irritable bowel syndrome; central nervous system disorders; Alzheimer's disease; cognition activators; analgesics; cardiovascular disorders; antidiabetic agents; sleep disorders | PFIZER INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20080269211-A1 | Indazole Derivatives | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1910340-A1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | Pfizer, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010390-A1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269211-A1 | Indazole Derivatives | GPR119, HRH4, HTR4 | ALDH1A1 1475/4885USP2 4524/4885ALOX15 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.